According to surveys, the overall morbidity rate of dyslipidemia groups
aged 18 and above is over 20% in China, and total patients are over 200
million nationwide. Blood lipid levels and morbidity rate of
dyslipidemia of Chinese people are still lower than that in most
developed countries. However, with the development of China's economy,
improvement in people's living standards and changes in lifestyle, the
morbidity rate of dyslipidemia gradually rises. Meanwhile, diabetes and
metabolic syndrome closely related to dyslipidemia are also common in
China.

According to market research, the market size of China's hypolipidemic
drugs exceeded CNY 12 billion in 2011, with an annual growth rate of
over 15 %.

At present, blood lipid controlling drugs in the Chinese market are
mainly divided into five categories: statins, fibrates, nicotinic acids,
resins and cholesterol absorption inhibitors, also including some other
drugs. Statins and fibrates occupy the largest market share in the
Chinese market, and applications of other drugs are relatively a few. In
terms of the market share of major varieties, the total market share of
the top 5 hypolipidemic drug varieties in China was over 80% in 2009.
Among them, the top 4 products all were statins (respectively:
Atorvastatin, Simvastatin, Pravastatin and Fluvastatin), which occupied
nearly 80% of the market share. In 2011, the market share of the top 5
varieties in China's hypolipidemic market was 82.64%. Among them, the
top 4 products were still statins (respectively: Atorvastatin,
Simvastatin, Pravastatin and Fluvastatin), which accounted for 78% of
the share. It is obvious that statin products are main forces in
hyperlipidemia treatment drug market of China. Statins are always in
leading positions in China's hypolipidemic drug market. Because of
excellent effects, little side effects and other multiple effects
including lowering overall mortality rate, statin drugs are major drugs
in the joint lipid-lowering program, thus occupying a most advantageous
position clinically.

The overall performance of China's hypolipidemic drugs in the drug
market is better than that of the entire drug and cardiovascular system
drug markets, showing a strong growth momentum. The expansion speed of
hypolipidemic drug market is evidently higher than that of the
cardiovascular drug market, and the proportion in cardiovascular system
drugs gradually rises.